Clinical trialNCT02293837CompletedPhase 2Interventional

Tocilizumab (TCZ) in New-onset Type 1 Diabetes

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment136New-onset Type 1 Diabetes MellitusT1DT1DMType 1 Diabetes Mellitus

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Based on previous research, study doctors think that giving medicines to affect the immune system soon after diabetes is diagnosed may stop, delay or decrease the destruction of beta cells, resulting in better glucose control. Researchers believe that tocilizumab could have some effect on the cells in the immune system that are thought to be involved in the development of type 1 diabetes. This study will test whether tocilizumab can help preserve or delay destruction of remaining beta cells in people recently diagnosed type 1 diabetes.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Carla Greenbaum
Benaroya Research Institute at Virginia Mason: Diabetes Research Program
Study Chair
clinicaltrials.gov ↗
Jane Buckner, M.D.
Benaroya Research Institute at Virginia Mason: Diabetes Research Program
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

the Children'S Hospital at Westmead: Kids Research Institute
Westmead, New South Wales, Australia
Lady Cilento Children'S Hospital: Department of Endocrinology
South Brisbane, Queensland, Australia

United States

University of California San Francisco
San Francisco, California, United States
Stanford University
Stanford, California, United States
Yale University School of Medicine: Diabetes Endocrinology Research Center
New Haven, Connecticut, United States
University of Florida
Gainesville, Florida, United States
University of Miami: Diabetes Research Institute
Miami, Florida, United States
University of South Florida: Diabetes Center
Tampa, Florida, United States
Indiana University Health - Riley Hospital for Children
Indianapolis, Indiana, United States
University of Iowa
Iowa City, Iowa, United States
Harvard University, Joslin Diabetes Center
Boston, Massachusetts, United States
University of Minnesota
Minneapolis, Minnesota, United States
Children'S Mercy Hospital
Kansas City, Missouri, United States
Columbia University, Naomi Berrie Diabetes Center
New York, New York, United States
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Sanford Research
Sioux Falls, South Dakota, United States
Vanderbilt University
Nashville, Tennessee, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Benaroya Research Institute
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PlaceboTocilizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 12 Mar 2015
Primary completion: 10 Jul 2019
Completion: 31 Aug 2020
Last update posted: 8 Sept 2021
Registered enrollment: 136
Registry id: NCT02293837

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.